Dean of the College of Science, Professor of Biochemistry, Rochester Institute of Technology
Consultant Microbiologist, Beaumont Hospital, Dublin, Ireland and Professor and Head of Department, Clinical Microbiology, RCSI University of Medicine and Health Sciences
Pesquisadora de pós-doutorado em saúde pública, Escola de Administração de Empresas de São Paulo da Fundação Getúlio Vargas (FGV/EAESP)
Professor of Biocchemistry and Biomedical Sciences, McMaster University
Catedrático de Microbiología. Miembro de la Sociedad Española de Microbiología., Universidad de Salamanca
Honorary Professorial Fellow, medical microbiology, The University of Melbourne
Associate Professor of Pharmaceutical Sciences, Universitas Andalas
André O. Hudson receives funding from the National Institutes of Health.
Lori L. Burrows receives research grants from the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, Glyconet, and the Ontario Research Fund.
Roy Robins-Browne has received funding from The Australian National Health and Medical Research Council, The Australian Research Council, the Bill and Melinda Gates Research Foundation and The US National Institutes of Health.
Fidelma Fitzpatrick, Juliana Côrrea, Raúl Rivas González, and Yori Yuliandra do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.
University of Melbourne provides funding as a founding partner of The Conversation AU.
McMaster University provides funding as a founding partner of The Conversation CA.
Universidad de Salamanca provides funding as a founding partner of The Conversation ES.
McMaster University provides funding as a member of The Conversation CA-FR.
Rochester Institute of Technology provides funding as a member of The Conversation US.
RCSI University of Medicine and Health Sciences provides funding as a member of The Conversation UK.
FGV/EAESP provides support as an endorsing partner of The Conversation BR.
Almost since antibiotics were first discovered, we’ve been aware bacteria can learn how to overcome these medicines, a phenomenon known as antimicrobial resistance.
The World Health Organization says we’re currently losing to the bugs, with resistance increasing and too few new antibiotics in the pipeline.
We wanted to know whether experts around the world think we will still have effective antibiotics in 50 years. Seven out of seven experts said yes.
Write an article and join a growing community of more than 182,600 academics and researchers from 4,945 institutions.
